Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Travel, energy stocks drag UK shares lower, weighed by coronavirus fears

10/26/2020 | 05:26am EST

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)

* Surge in coronavirus cases dents mood

* EU negotiator Barnier extends London visit for Brexit talks

* AstraZeneca gains on positive COVID-19 vaccine update

* Coca-Cola European Partners rise on buyout offer

* FTSE 100 down 1.2%, FTSE 250 drops 1.4%

Oct 26 (Reuters) - London stocks closed sharply lower on Monday, weighed by travel and energy stocks, while a resurgence in novel coronavirus cases stoked fears of a faltering economic recovery and dragged down European markets. After rising nearly 0.1% in morning trade, the blue-chip FTSE 100 index fell 1.2%, led by declines in travel and leisure, personal goods makers, retailers and aero stocks.

Energy and mining weighed the most on the index due to weaker commodity prices.

The domestically focussed mid-cap FTSE 250 index lost 1.4% even as European Union chief negotiator Michel Barnier and his team extended their London visit until Wednesday to try and clinch a Brexit trade deal.

European markets were weighed down by a plunge in tech major SAP, an impasse over the U.S. stimulus package and fears that a resurgence in coronavirus cases could hamper a global economic recovery as governments tighten restrictions on businesses and social activity.

"The fact that (more) countries are now reining in the freedom of people to move around is going to have a detrimental impact on the actual overall activity level in the economy", said Saxo Bank chief investment officer Steen Jakobsen.

"UK is even more challenged due to the COVID-19 close-down and Brexit."

After a stimulus-backed rally from pandemic lows, the FTSE 100 has been trading in tight ranges since June due to Brexit-related uncertainty and concerns over coronavirus curbs.

In a bright spot, AstraZeneca Plc rose 1.7% after the drugmaker resumed the U.S. trial of its experimental COVID-19 vaccine that is being developed with the University of Oxford, and said it produced a similar immune response in both older and younger adults.

The wider healthcare index added 1%.

Educational publisher Pearson Plc added 3% after UBS upgraded the stock to a "buy" rating.

Coca-Cola European Partners (CCEP) rose 0.3% after the soft drink bottler made a buyout offer of $6.6 billion for its Australian peer Coca-Cola Amatil Ltd. (Reporting by Devik Jain in Bengaluru; editing by Aditya Soni and Bernadette Baum)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.68% 7880 Delayed Quote.4.34%
COCA-COLA AMATIL LIMITED 0.47% 12.73 End-of-day quote.15.10%
EURO / BRITISH POUND (EUR/GBP) -0.39% 0.90246 Delayed Quote.6.36%
MSCI UNITED KINGDOM (STRD, UHD) 1.04% 1009.276 Real-time Quote.-16.09%
PEARSON PLC 0.18% 675.6 Delayed Quote.5.75%
SAP SE -1.24% 100.08 Delayed Quote.-15.81%
All news about ASTRAZENECA PLC
04:21aMerck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
RE
04:02aMerck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
RE
02:57aS.Korea shares close at record high on chip, auto boost
RE
02:17aASTRAZENECA : demonstrates growing leadership in breast cancer at SABCS with dat..
PU
01:09aASTRAZENECA : South Korea reaches deal to buy AstraZeneca's COVID-19 vaccine can..
RE
12/02Pfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 7th Update
DJ
12/02Pfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 6th Update
DJ
12/02ASTRAZENECA : U.S. COVID-19 vaccine trial results likely in late-Jan, says healt..
RE
12/02PFIZER, BIONTECH'S COVID-19 VACCINE : What You Need to Know
DJ
12/02ASTRAZENECA : As coronavirus soars, U.S. cheers Britain's vaccine approval
RE
More news
Financials (USD)
Sales 2020 26 494 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 44,6x
Yield 2020 2,65%
Capitalization 139 B 139 B -
EV / Sales 2020 5,75x
EV / Sales 2021 5,01x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,91 $
Last Close Price 106,11 $
Spread / Highest target 46,5%
Spread / Average Target 14,9%
Spread / Lowest Target -37,8%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC4.34%138 967
JOHNSON & JOHNSON1.56%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.9.91%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033